Effects of alendronic acid on bone strength, soft tissue mass and bone turnover markers in treatment-naive postmenopausal Japanese women with osteoporosis

Trial Profile

Effects of alendronic acid on bone strength, soft tissue mass and bone turnover markers in treatment-naive postmenopausal Japanese women with osteoporosis

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2013

At a glance

  • Drugs Alendronic acid (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 28 Nov 2013 New trial record
    • 08 Oct 2013 Results presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top